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Role of IgE in Eosinophilic Otitis Media
Yukiko Iino1
ABSTRACT
Eosinophilic otitis media (EOM) is an intractable otitis media characterized by the presence of a highly viscous
yellow effusion containing eosinophils. It mainly occurs in patients with bronchial asthma and is resistant to
conventional treatments for otitis media. Here we discuss the role of IgE in the pathogenesis of EOM. In middle
ear effusion, a significantly higher IgE level was detected in EOM patients than in control patients with common
otitis media with effusion. This IgE level was significantly higher (about 10 fold) than the serum IgE level. In ad-
dition, many IgE-immunopositive cells were found in the middle ear mucosa. The IgE staining was mainly ob-
served on mast cell surfaces, but also partially in the cytoplasm of cells that appeared to be plasma cells.
These results suggested that IgE is produced locally in the middle ear mucosa. The existence of high-level IgE
may exacerbate eosinophilic inflammation in the middle ear. One of the most distinct characteristics of EOM is
the high incidence of sensory hearing loss independent of age. High-tone hearing loss is more frequently found
and more severe in EOM patients than in control patients with common chronic otitis media. The concentration
of IgE in middle ear effusion significantly and positively correlated with bone conduction hearing levels at 2 kHz
and 4 kHz in EOM patients. Overproduction of IgE locally in the middle ear may be related to the pathological
condition of EOM and eventually cause inner ear damage.
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INTRODUCTION
Eosinophilic otitis media (EOM) is an intractable oti-
tis media characterized by the presence of a highly
viscous yellow effusion containing eosinophils. It
mainly occurs in patients with bronchial asthma and
is resistant to conventional treatments for otitis me-
dia. In 1993, Tomoioka et al.1 first reported on three
cases of patients suffering from intractable otitis me-
dia associated with bronchial asthma as a new middle
ear disease entitiy. They proposed to name this otitis
media eosinophilic otitis media (EOM) in 1997.2 To-
day, 13 years after the proposal, cases of this disease
have accumulated and the clinical characteristics of
the disease have become clear. Not only is EOM an
intractable and persistent disease, it also presents a
high risk of developing severe hearing loss (deafness
in some cases).1-3 The pathological condition of this
disease has been demonstrated as active inflamma-
tion of the middle ear with production of various
chemical mediators that induce migration of eosino-
phils in the middle ear mucosa.4-6 In patients with
EOM, high concentration of immunoglobulin E
(IgE), playing a crucial role in type I allergic reaction,
is detected in middle ear effusion. In addition, many
IgE-immunopositive cells were found in the middle
ear mucosa,4 indicating that IgE is potentially related
to the pathological condition of EOM. In this paper,
we discuss the role of IgE in the pathogenesis of
EOM.
PATHOGENESIS OF EOM
MECHANISM OF INFILTRATION OF EOSINO-
PHILS INTO THE MIDDLE EAR
Histological examination of middle ear effusion
showed that a large number of eosinophils, which are
considered to be eosinophilic mucin, in addition to a
mucus component, was observed. Many of these
eosinophils are degranulated, and some eosinophils
exhibit cytolysis with the nucleus breaking out of the
cells (Fig. 1). However, there are not as many eosino-
phils observed in the middle ear mucosa as in the
middle ear effusion (Fig. 2). It is considered that
eosinophils that migrated to the middle ear mucosa
do not stay locally in the middle ear but migrate im-
mediately to the middle ear cavity. In contrast, nasal
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Fig. 1 Histological section of middle ear efusion in a pa
tient with EOM (HE stainings).
Fig. 2 Histological and immunohistological sections of middle ear mucosa in a patient with eosinophilic 
otitis media.
HE EG2
Fig. 3 Histological and immunohistological sections of paranasal sinus mucosa in a patient with eosino
philic chronic rhinosinusitis.
HE EG2
polyps and the paranasal sinus mucosa of patients
with eosinophilic chronic rhinosinusitis show exten-
sive accumulation of eosinophils in the submucosa
(Fig. 3). Therefore, the mechanism of eosinophil mi-
gration and survival may be slightly different between
middle ear mucosa and paranasal mucosanasal pol-
yps.
Eosinophil cationic protein (ECP) is an eosinophil-
derived cytoplasmic protein and is a marker for
eosinophilic inflammation. The concentration of ECP
in the middle ear effusion of EOM patients was sig-
nificantly higher than that in the control patients with
common otitis media with effusion.4 Moreover, a sig-
nificantly larger number of EG2-positive cells were
observed in the middle ear mucosa of EOM patients
than in the control patients, proving that active
eosinophilic inflammation is occurring in EOM.4 Re-
garding eosinophil chemoattractants, the concentra-
tions of IL-5 and eotaxin in middle ear effusion were
significantly higher in EOM patients than in the con-
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Fig. 4 Concentrations of eosinophil chemoatractants in 
middle ear efusion in patients with eosinophilic otitis media 
(EOM) and in patients with common otitis media with efu
sion (controls).
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Fig. 5 Concentrations of ECP and IgE in middle ear efu
sion in patients with eosinophilic otitis media (EOM) and in 
patients with common otitis media with efusion (controls).
30000
25000
20000
15000
10000
5000
0
P < 0.001 P < 0.01
ECP IgE 
EOM EOMControls Controls
ECP (μg/L) IgE (×10 U/ml)
Fig. 6 Concentrations of ECP and IgE in middle ear efu
sion and serum in patients with eosinophilic otitis media.
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trol group (Fig. 4).5,6 However, no significant differ-
ence in regulated on activation normal T cell ex-
pressed and secreted (RANTES) level was observed
between the EOM patients group and the control
group (Fig. 1).6 ECP concentration positively corre-
lated with that of IL-5. IL-5 is a cytokine involved in
not only eosinophil migration but also local activation
of eosinophils and increased cell survival. IL-5 is con-
sidered to be most highly involved in the pathological
condition of eosinophilic inflammation in EOM.
Immunohistochemically, the number of cells im-
munopositive for IL-5 and ecalectin, which are the
chemotactic and activating factors for eosinophils,
significantly increased in the middle ear mucosa of
EOM patients compared with that of the control pa-
tients. Furthermore, the expressions of eotaxin, RAN-
TES and ecalectin mRNAs were detected by in situ
hybridization.6 The fact that chemotactic and activat-
ing factors for eosinophils were detected not only at
the protein level but also at the mRNA level, indicated
that active eosinophilic inflammation occurs in the
middle ear itself.
IgE IN EOM
IgE is an immunoglobulin produced by B lympho-
cytes, and plays an important role in type I allergic re-
actions. IgE binds to the surface of mast cells, and
the mast cells degranulate when an antigen binds and
bridges two IgEs, releasing many types of chemical
substance that cause various inflammatory condi-
tions. Although an increased antigen-specific IgE
level is not always detected in patients with EOM,
many of them showed higher levels of total IgE in se-
rum. A significantly higher IgE level, similar to ECP
level, was detected in middle ear effusion in the EOM
patient group than in the control group (Fig. 5).7 This
IgE level was significantly higher (about 10 fold) than
serum IgE level, and hence IgE in the former is con-
sidered to have been produced locally in the middle
ear (Fig. 6).7 Immunohistological examination also
showed many IgE-positive cells in the middle ear mu-
cosa. The immunostainings of IgE was generally ob-
served on mast cell surfaces, but also partially in the
cytoplasm of cells that appeared to be plasma cells
(Fig. 7).4 IgE is therefore considered to be produced
locally in the middle ear mucosa. Bachert et al.8 re-
ported that significant concentrations of IgE specific
to Staphylococcus aureus enterotoxins A and B were
detected in the nasal polyp tissue from patients with
chronic rhinosinusitis. As the patients showed no in-
crease in antigen-specific IgE level in serum or no
positive reaction in skin test, they concluded that IgE
was produced locally in nasal polyps. Staphylococcus
aureus enterotoxins A and B also have the properties
of superantigens which can strongly stimulate IgE
production. In case of EOM, substance(s) that stimu-
lates IgE production in the middle ear is as yet unde-
termined, and this should be investigated in detail in
the future.
In type I allergic reaction, eosinophils also play an
important role in the late phase of reaction. In an ani-
mal model, it was also reported that not IgG1 but IgE
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Fig. 7 A immunohistological section of middle ear mucosa 
of a patient with EOM. Many IgE-immunopositive cels are 
seen in the submucosa.
Fig. 8 Role of eosinophils in inflammatory conditions.
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is involved in airway inflammation and hypersensitiv-
ity in the late phase of reaction in bronchial asthma.9
FcεRI, a high-affinity receptor of IgE, was found in
eosinophils and the pathway for the release of cyto-
toxic proteins from eosinophils was demonstrated as
an IgE-dependent hypersensitivity reaction.10 The ex-
istence of high-level IgE may exacerbate eosinophilic
inflammation in the middle ear together with various
cellular factors such as reactive oxygen species, cy-
tokines, and chemokines released by eosinophils
(Fig. 8).
SENSORY HEARING LOSS AND IgE IN EOM
Patients with EOM have conductive hearing loss in
the initial stage but begin to develop mixed-type hear-
ing loss during the course of the disease. It was re-
ported that some patients exhibited an increased
bone-conduction threshold, which led to deafness in
some of them.1-3 An epidemiological survey in Japan
showed that 47% of patients showed an increased
bone conduction hearing level (BCHL), 6% of which
eventually became deaf.11 Generally, the type of hear-
ing loss in patients with EOM is mostly high-tone
loss.12 However, it is generally accepted that ears
with common type of chronic otitis media also show
gradual sensorineural hearing loss compared with
healthy ears,13,14 and in these studies, a significant in-
crease in BCHL was also found at higher frequencies.
It seems likely that the BCHL deterioration associ-
ated with EOM is one of the symptoms, which is
sometimes observed in COM. Therefore, we com-
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Fig. 9 Bone conduction hearing level of patients with eosinophilic otitis media (EOM: 65 ears) 
and common chronic otitis media (controls: 71 ears).
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pared BCHL in non-eosinophilic chronic otitis media
patients who had undergone tympanoplasty (control
group) with that in patients with EOM (EOM group),
and found that the incidence and extent of increase in
BCHL in high frequencies were significantly higher
in the latter group. The difference was notably signifi-
cant in patients in their 50s (Fig. 9).15 Nakagawa et
al.16 reported that in case of EOM, BCHLs at 4000
and 8000 Hz were higher than those at lower frequen-
cies, and the loss rate was about 10 times that in case
of COM, which was reported by Cusimano et al.17 In
our study, the infected ear with granulomatous otitis
media was often accompanied by a significant in-
crease in BCHL.15 These findings suggest that bacte-
rial infection and eosinophilic inflammation in the
middle ear might exert a synergistic effect on inner
ear damage.
We measured the concentrations of ECP and IgE
in middle ear effusion as markers of eosinophilic in-
flammation,18,19 and analyzed the correlation between
these concentrations and BCHL in EOM patients to
determine whether eosinophilic inflammation is in-
deed related to the deterioration of BCHL. As the re-
sults, the concentration of IgE in middle ear effusion
significantly and positively correlated with BCHL at 2
kHz and 4 kHz.7 The ears with a higher concentra-
tion of ECP in middle ear effusion also tended to
show deterioration of BCHL at 4 kHz. Other clinical
risk factors for BCHL deterioration were male gen-
der, long duration of EOM, association with bacterial
infection, severe inflammatory changes of the middle
ear mucosa, and high serum IgE concentration.7
The mechanism underlying inner ear damage by
eosinophilic and bacterial inflammation is unclear.
Eosinophils are much more cytotoxic than neutro-
phils,20 because eosinophils can generate a higher
level of reactive oxygen species than neutrophils.21
The cytotoxic proteins and active oxygen species
generated by eosinophils may damage the epithelial
layer including the round window membrane, and
lipid mediators released from eosinophils render the
membrane permeable. These events allow inflamma-
tory substances such as bacterial toxins and inflam-
matory cytokines to enter into the inner ear, resulting
in inner ear damage. Sensory hearing loss varies
from stable over a long period of time in some pa-
tients to the rapid deterioration in other patients. The
IgE level in middle ear effusion may become a good
indicator of increase in BCHL.
CONCLUSIONS
Overproduction of IgE locally in the middle ear may
be related to the pathological condition of EOM and
eventually inner ear damage. Currently, an effective
treatment for EOM is administration of systemic and
topical corticosteroids,22 and irrigation of the middle
ear using saline-heparin solution.12 However, therapy
targeting IgE, that is, anti-IgE antibody therapy with
omalizumab for example, could establish to cure or
improve EOM.
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